Safety

Acne is a normal skin disease that afflicts approximately 50 million people in the United States every year. There is a formation of pimples when the follicles in the skin become barred. Pimples usually form on the face, back, neck, chest, and also on the shoulders.

Any individual can get acne, but it is most frequent in teens and young adults. Acne can be cured and have negative psychological impacts as of the low self-image, depression, and anxiety. There is a category of over the counter and non-prescription remedy options accessible for people with acne.

Pregnant women intending to become pregnant or breastfeeding should consult a doctor before the usage of Differin Gel. Although topical retinoids are often directed as first-line treatments for the acne of all grades, alone or in sequence with other treatments, Differin Gel 0.1% is the first retinoid treatment for acne.

Although there are no sufficient and well-controlled investigations with Differin Gel 0.1% in pregnant women, there is no definite evidence that Differin Gel 0.1% induces birth defects in women. Individuals when administered topically as directed and some other retinoids cause birth defects.

The safety and effectiveness of Differin Gel were originally learned from five clinical studies in people with mild to medium acne. In support of the OTC marketing assistance, post-market safety data, customer study data as a label understanding study, a self-selection study, and tangible use study, and peak use test data are accumulated from the year 1996 to 2016 to support OTC approval.

Overall, the results of customer studies have shown that individuals understand and acknowledge the details on the product, can correctly choose whether the outcome is right for them, and use the Differin Gel correctly.

The Maximum usage study, a study of drug retention through acne-prone skin when administered daily to a large area exposed that absorption is restricted and therefore promotes its usage.